Review

Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update

Volume: 42 Number: 2 June 1, 2022
TR EN

Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update

Abstract

Erectile dysfunction (ED) affects middle and older age and occurrence increasing with age of men. PDE5 inhibitors are commonly used for the treatment of ED. The incidences of adulteration of PDE5 inhibitors with herbal aphrodisiacs is evident in almost every part of world. Avanafil (AVA) is novel PDE5 inhibitor with advantage of fast action. The literatures and various analytical methods presented in this review was obtained by searching various databases like pubmed, medline, eurekaselect, sciencedirect, wiley and taylor and francis journals. The services of google scholar were also utilized for searching some literature. The literature search was performed to summarize characteristics, synthesis and analytical methods for determination of AVA. Different spectrophotometry methods, chromatography and ion mobility spectrometry methods are available in the method. The possibility for the development of green analytical method is also discussed. The various analytical methods and characteristics of AVA is described. The methods for determination as adulterants and in pharmaceutical formulations including stability indicating methods.

Keywords

References

  1. Reference1 Mitidieri E, Cirino G, d'Emmanuele di Villa Bianca R, Sorrentino R. Pharmacology and perspectives in erectile dysfunction in man. Pharmacol Ther. 2020;208:107493. DOI:10.1016/j.pharmthera.2020.107493.
  2. Reference2 Razdan S, Greer AB, Patel A, Alameddine M, Jue JS, Ramasamy R. Effect of prescription medications on erectile dysfunction. Postgrad Med J. 2018;94(1109):171-178. DOI:10.1136/postgradmedj-2017-135233.
  3. Reference3 Ahmed WS, Geethakumari AM, Biswas KH. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother. 2021;134:111128. DOI:10.1016/j.biopha.2020.111128.

Details

Primary Language

English

Subjects

Pharmacology and Pharmaceutical Sciences

Journal Section

Review

Publication Date

June 1, 2022

Submission Date

November 1, 2021

Acceptance Date

January 27, 2022

Published in Issue

Year 2022 Volume: 42 Number: 2

APA
Shrivastava, A. (2022). Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update. Hacettepe University Journal of the Faculty of Pharmacy, 42(2), 134-147. https://doi.org/10.52794/hujpharm.1017182
AMA
1.Shrivastava A. Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update. HUJPHARM. 2022;42(2):134-147. doi:10.52794/hujpharm.1017182
Chicago
Shrivastava, Alankar. 2022. “Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update”. Hacettepe University Journal of the Faculty of Pharmacy 42 (2): 134-47. https://doi.org/10.52794/hujpharm.1017182.
EndNote
Shrivastava A (June 1, 2022) Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update. Hacettepe University Journal of the Faculty of Pharmacy 42 2 134–147.
IEEE
[1]A. Shrivastava, “Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update”, HUJPHARM, vol. 42, no. 2, pp. 134–147, June 2022, doi: 10.52794/hujpharm.1017182.
ISNAD
Shrivastava, Alankar. “Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update”. Hacettepe University Journal of the Faculty of Pharmacy 42/2 (June 1, 2022): 134-147. https://doi.org/10.52794/hujpharm.1017182.
JAMA
1.Shrivastava A. Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update. HUJPHARM. 2022;42:134–147.
MLA
Shrivastava, Alankar. “Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update”. Hacettepe University Journal of the Faculty of Pharmacy, vol. 42, no. 2, June 2022, pp. 134-47, doi:10.52794/hujpharm.1017182.
Vancouver
1.Alankar Shrivastava. Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update. HUJPHARM. 2022 Jun. 1;42(2):134-47. doi:10.52794/hujpharm.1017182

Cited By